← All trials
NCT05245682
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 17, 2022
- Primary completion
- Oct 21, 2024
- Completion date
- Oct 21, 2025
- First posted
- Feb 18, 2022
- Last posted
- Feb 21, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- Astex Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.